NCT06742463 - VHAG in Treating R/R T-ALL/LBL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions

Acute T Lymphpblastic Leukemia/Lymphoma

Interventions

DRUG

Venetoclax

BCL-2 inhibitor

DRUG

homoharringtonine

alkaloid

DRUG

Cytarabine (Ara-C)

Metabolic antagonist.

DRUG

G-CSF

Granulocyte colony-stimulating factor

Trial Locations (1)

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER